Business Overview
BIO-key International develops and markets proprietary fingerprint identification biometric technology and enterprise-ready identity access management solutions for commercial, government, and education customers. During Q1 2026, the company is implementing strategic initiatives including restructuring its EMESA subsidiary to focus on higher-margin BIO-key and PortalGuard solutions, and monetizing delayed inventory from Nigeria projects by selling into other markets to improve cash generation.
Segment Performance
Q1 2026 revenue of $2.1 million increased 33% versus Q1 2025 revenue of $1.6 million. By segment: Services revenue declined from $272.6K to $248.4K; License fees increased from $1.1M to $1.4M; Hardware increased significantly from $235.8K to $531.3K. By geography: North America declined from $578.3K to $445.3K; Africa increased from $589.2K to $924.1K; EMESA increased from $408.1K to $753.8K; Asia declined from $31.5K to $22.3K. Gross profit improved to $1.8M in Q1 2026 versus $1.3M in Q1 2025. Operating loss improved to $(157.7K) versus $(640.6K) prior year. Net loss improved to $(205.0K) versus $(736.5K).
Key Risk Factors
The company faces substantial doubt about its ability to continue as a going concern due to a history of losses, negative operating cash flow, and dependence on obtaining additional financing. The company holds a significant equity investment in early-stage pre-revenue company Boumarang, Inc. with inherent uncertainty regarding recoverability and fair value determination. Foreign currency fluctuations, particularly in the Euro, Naira, and Hong Kong Dollar, impact consolidated results. The company carries a large inventory reserve ($3.2 million on finished goods of $3.4 million) due to slow-moving inventory purchased for delayed Nigeria projects.
